Human embryonic and induced pluripotent stem cells in cardiovascular drug discovery: Patents and patented uses

Recent Patents on Cardiovascular Drug Discovery

Volumn 6, Issue 3, 2011, Pages 199-206

  Ivashchenko, Christine Y ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cardiac repair; Cardiomyocyte; Differentiation; Hes; Hips

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CARDIOVASCULAR AGENT; CELL SURFACE MARKER; KRUPPEL LIKE FACTOR 4; LEUKEMIA INHIBITORY FACTOR; MITOMYCIN C; OCTAMER TRANSCRIPTION FACTOR 4; TISSUE SCAFFOLD; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; WNT PROTEIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CELL CULTURE; CELL AGGREGATION; CELL CULTURE; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL DIVISION; CELL IMMORTALIZATION; CELL ISOLATION; CELL LINEAGE; CELL POPULATION; CELL RENEWAL; CHIMERA; CLINICAL TRIAL (TOPIC); DNA MODIFICATION; DRUG DEVELOPMENT; EMBRYO DEVELOPMENT; EMBRYOID BODY; EMBRYONIC STEM CELL; ENDODERM; EPIGENETICS; GENE TARGETING; GENETIC ASSOCIATION; GENETIC RECOMBINATION; GENETIC SELECTION; HEART DEVELOPMENT; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE METABOLISM; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; INNER CELL MASS; NONHUMAN; ONCOGENE C MYC; OOCYTE; PATENT; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SOMATIC CELL; TARGET CELL; TERATOMA; TISSUE DIFFERENTIATION; TISSUE ENGINEERING; TISSUE REGENERATION; TOTIPOTENT STEM CELL; TRANSGENICS;

EID: 80053482548     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489011797377077     Document Type: Review

References (89)

1. Mitalipov S, Wolf D. Totipotency, pluripotency and nuclear reprogramming. Adv Biochem Eng Biotechnol 2009; 114: 185-199.
2. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282(5391): 1145-1147.
3. Thomson JA, Marshall VS. Primate embryonic stem cells. Curr Top Dev Biol 1998; 38: 133-165.
4. Ramalho-Santos M, Willenbring H. On the origin of the term stem cell. Cell Stem Cell 2007; 1(1): 35-38.
5. Becker AJ, Mc CE, Till JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 1963; 197: 452-454.
6. Siminovitch L, McCulloch EA, Till JE. The distribution of colonyforming cells among spleen colonies. J Cell Physiol 1963; 62: 327-336.
7. Till JE, Mc CE. Early repair processes in marrow cells irradiated and proliferating in vivo. Radiat Res 1963; 18: 96-105.
8. Kleinsmith LJ, Pierce GB Jr. Multipotentiality of single embryonal carcinoma cells. Cancer Res 1964; 24: 1544-1551.
9. Andrews PW. From teratocarcinomas to embryonic stem cells. Philos Trans R Soc Lond B Biol Sci 2002; 357(1420): 405-417.
10. Andrews PW. Teratocarcinomas and human embryology: Pluripotent human EC cell lines. Review article. APMIS 1998; 106(1): 158-167; discussion 167-8.
11. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci USA 1981; 78(12): 7634-7638.
12. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981; 292(5819): 154-156.
13. Resnick JL, Bixler LS, Cheng L, Donovan PJ. Long-term proliferation of mouse primordial germ cells in culture. Nature 1992; 359(6395): 550-551.
14. Pease S, Braghetta P, Gearing D, Grail D, Williams RL. Isolation of embryonic stem (ES) cells in media supplemented with recombinant leukemia inhibitory factor (LIF). Dev Biol 1990; 141(2): 344-352.
15. Conquet F, Brulet P. Developmental expression of myeloid leukemia inhibitory factor gene in preimplantation blastocysts and in extraembryonic tissue of mouse embryos. Mol Cell Biol 1990; 10(7): 3801-3805.
16. Smith AG, Heath JK, Donaldson DD, Wong GG, Moreau J, Stahl M, et al. Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature 1988; 336(6200): 688-690.
17. Xu C, Rosler E, Jiang J, Lebkowski JS, Gold JD, O'Sullivan C, et al. Basic fibroblast growth factor supports undifferentiated human embryonic stem cell growth without conditioned medium. Stem Cells 2005; 23(3): 315-323.
18. Thomson, J.A. Primate embryonic stem cell line. US7582479 (2009).
19. Thomson, J.A., Spontaneous differentiation of human embryonic stem cells in culture. US7781216 (2010).
20. Thomson, J.A., Levenstein, M. Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium. US7439064 (2008).
21. Bergendahl, V., Thomson, J.A. Clonal culture of human pluripotent stem cells. US7892830 (2011).
22. Zhang, S.-C., Du, Z.-W. Gene recombination exchange system for stable gene modification in human ES cells. US7947501 (2011).
23. Xu, C., Li, Y., Mandalam R. Medium for growing human embryonic stem cells. US7455983 (2008).
24. Carpenter, M.K., Inokuma, M.S., Xu, C. Use of human embryonic stem cells for drug screening and toxicity testing. US7041438 (2006).
25. Tada M, Tada T, Lefebvre L, Barton SC, Surani MA. Embryonic germ cells induce epigenetic reprogramming of somatic nucleus in hybrid cells. EMBO J 1997; 16(21): 6510-6520.
26. Wilmut I, Schnieke AE, McWhir J, Kind AJ. CampbellKH. Viable offspring derived from fetal and adult mammalian cells. Nature 1997; 385(6619): 810-3.
27. Terada N, Hamazaki T, Oka M, Hoki M, Mastalerz DM, Nakano Y, et al. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature 2002; 416(6880): 542-545.
28. Ying QL, Nichols J, Evans EP, Smith AG. Changing potency by spontaneous fusion. Nature 2002; 416(6880): 545-548.
29. Walker E, Ohishi M, Davey RE, Zhang W, Cassar PA, Tanaka TS, et al. Prediction and testing of novel transcriptional networks regulatin embryonic stem cell self-renewal and commitment. Cell Stem Cell 2007; 1(1): 71-86.
30. Niwa H. Open conformation chromatin and pluripotency. Genes Dev 2007; 21(21): 2671-2676.
31. Pan G, Thomson JA. Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell Res 2007; 17(1): 42-49.
32. Eiselleova L, Matulka K, Kriz V, Kunova M, Schmidtova Z, Neradil J, et al. A complex role for FGF-2 in self-renewal, survival, and adhesion of human embryonic stem cells. Stem Cells 2009; 27(8): 1847-1857.
33. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126(4): 663-676.
34. Okita K, Ichisaka T, Yamanaka S. Generation of germlinecompetent induced pluripotent stem cells. Nature 2007; 448(7151): 313-317.
35. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131(5): 861-872.
36. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318(5858): 1917-1920.
37. Jaenisch, R., Hochedlinger, K. Methods for reprogramming somatic cells. US7682828 (2010).
38. Yazawa M, Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011; 471(7337): 230-234.
39. Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011; 471(7336): 68-73.
40. Itskovitz-Eldor J, Schuldiner M, Karsenti D, Eden A, Yanuka O, Amit M, et al. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol Med 2000; 6(2): 88-95.
41. Thomson, J.A., Marshall, V.S., Swiergiel, J.J. Method of making embryoid bodies from primate embryonic stem cells. US7220584 (2007).
42. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009; 104(4): e30-41.
43. Schuldiner M, Yanuka O, Itskovitz-Eldor J, Melton DA, Benvenisty N. Effects of eight growth factors on the differentiation of cells derived from human embryonic stem cells. Proc Natl Acad Sci USA 2000; 97(21): 11307-11312.
44. van Wijk B, Moorman AF, van den Hoff MJ. Role of bone morphogenetic proteins in cardiac differentiation. Cardiovasc Res 2007; 74(2): 244-355.
45. Taha, MF, Valojerdi MR, Mowla SJ. Effect of bone morphogenetic protein-4 (BMP-4) on cardiomyocyte differentiation from mouse embryonic stem cell. Int J Cardiol 2007; 120(1): 92-101.
46. Kruithof BP, van Wijk B, Somi S, Kruithof-de Julio M, Perez Pomares JM, Weesie F, et al. BMP and FGF regulate the differentiation of multipotential pericardial mesoderm into the myocardial or epicardial lineage. Dev Biol 2006; 295(2): 507-522.
47. Yuasa S, Itabashi Y, Koshimizu U, Tanaka T, Sugimura K, Kinoshita M, et al. Transient inhibition of BMP signaling by Noggin induces cardiomyocyte differentiation of mouse embryonic stem cells. Nat Biotechnol 2005; 23(5): 607-611.
48. Kawai T, Takahashi T, Esaki M, Ushikoshi H, Nagano S, Fujiwara H, et al. Efficient cardiomyogenic differentiation of embryonic stem cell by fibroblast growth factor 2 and bone morphogenetic protein 2. Circ J 2004; 68(7): 691-702.
49. Hidai C, Masako O, Ikeda H, Nagashima H, Matsuoka R, Quertermous T, et al. FGF-1 enhanced cardiogenesis in differentiating embryonal carcinoma cell cultures, which was opposite to the effect of FGF-2. J Mol Cell Cardiol 2003; 35(4): 421-425.
50. Keller, G.M., Kouskoff, V., Kubo, A., Fehling, H.J. Method of enriching a mammalian cell population for mesoderm cells. US7955849 (2011)
51. Keller, G.M., Keller, G.M., Kouskoff, V., Kubo, A., Fehling, H.J. Mesoderm and definitive endoderm cell populations. US7763466 (2010).
52. Gold, J.D., Hassanipour, M., Collins, L.R., Xu, C. Direct differentiation method for making cardiomyocytes from human embryonic stem cells. US7897389 (2011).
53. Xu, C., Gold, J.D. Process for making transplantable cardiomyocytes from human embryonic stem cells. US7732199 (2010).
54. Xu, C. Differentiation protocol for making human cardiomyocytes. US7763464 (2010).
55. Blin G, Nury D, Stefanovic S, Neri T, Guillevic O, Brinon B, et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J Clin Invest 120(4): 1125-1139.
56. Gay, D.A. Method of isolating a lineage specific stem cell in vitro. US5639618 (1997)
57. Smith, A.G., Li M. Lineage specific cells and progenitor cells. US7781214 (2010).
58. McWhir, J., Gold J.D., Schiff J.M. Selective antibody targeting of undifferentiated stem cells. US6921665 (2005).
59. Yutzey KE, Robbins E. Principles of genetic murine models for cardiac disease. Circulation 2007; 115(6): 792-799.
60. Xu, C. Compound screening using cardiomyocytes. US7851167 (2010).
61. Martin-Rendon E, Blake DJ. Patenting human genes and stem cells. Recent Pat DNA Gene Seq 2007; 1(1): 25-34.
62. Bergman K, Graff GD. The global stem cell patent landscape: implications for efficient technology transfer and commercial development. Nat Biotechnol 2007; 25(4): 419-424.
63. Brunner S, Engelmann MG, Franz WM. Stem cell mobilisation for myocardial repair. Expert Opin Biol Ther 2008; 8(11): 1675-1690.
64. Dawn B, Tiwari S, Kucia MJ, Zuba-Surma EK, Guo Y, Sanganalmath SK, et al. Transplantation of bone marrow-derived very small embryonic-like stem cells attenuates left ventricular dysfunction and remodeling after myocardial infarction. Stem Cells 2008; 26(6): 1646-1655.
65. Zhang N, Mustin D, Reardon W, Almeida AD, Mozdziak P, Mrug M, et al. Blood-borne stem cells differentiate into vascular and cardiac lineages during normal development. Stem Cells Dev 2006; 15(1): 17-28.
66. Marsboom G, Janssens S. Endothelial progenitor cells: new perspectives and applications in cardiovascular therapies. Expert Rev Cardiovasc Ther 2008; 6(5): 687-701.
67. Reffelmann, T, Konemann S, Kloner RA. Promise of blood- and bone marrow-derived stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy. J Am Coll Cardiol 2009; 53(4): 305-308.
68. Evans SM, Mummery C, Doevendans PA. Progenitor cells for cardiac repair. Semin Cell Dev Biol 2007; 18(1): 153-160.
69. Kaufman, D.S., Thomson J.A. Hematopoietic differentiation of human embryonic stem cells. US6613568 (2003).
70. Edelberg, J., Rafii, S., Hong, M., Lanza, R.P., West, M.D. Endothelial precursor cells for enhancing and restoring vascular function. US7135171 (2006).
71. Xiao, Y.F., Morgan, J.P. Genetically altered mammalian embryonic stem cells, their living progeny, and their therapeutic application for improving cardiac function after myocardial infarction. US6607720 (2003).
72. Alt, E., Method of transluminal application of myogenic cells for repair or replacement of heart tissue. US6805860 (2004).
73. Xu, C., Cardiomyocyte precursors from human embryonic stem cells. US7425448 (2008).
74. Alt, E., Transluminal application of adult stem cells for body organ tissue repair. US7452532 (2008).
75. Nayak, A.S., Bonner, M.D., Rothstein, P.T., Hiniduma-Lokuge, P.D., Keogh, J.R., Usher, R.W., Jahns, S.E., Chen, V.T. Devices and methods for interstitial injection of biologic agents into tissue. US7740623 (2010).
76. Eriksson, P., Karin, E., Tallheden, T., Enerback, S. Method for efficient transfer of human blastocyst-derived stem cells (hBS cells) from a feeder-supported to a feeder-free culture system, long-term propagation of hBS cells under feeder-free conditions and use of cultured hBS cells for applications in myocardial regeneration. US7638328 (2009).
77. Anversa, P. Methods and compositions for the repair and/or regeneration of damaged myocardium. US7862810 (2011).
78. Fukuda, K., Method of inducing the differentiation of stem cells into myocardial cells. US7727762 (2010).
79. Boyle AJ, Schulman SP, Hare JM. Is stem cell therapy ready for patients? Stem cell therapy for cardiac repair ready for the next step. Circulation 2006; 114(4): 339-352.
80. Roccio M, Goumans MJ, Sluijter JP, Doevendans PA. Stem cell sources for cardiac regeneration. Panminerva Med 2008; 50(1): 19-30.
81. Shiba Y, Hauch KD, Laflamme MA. Cardiac applications for human pluripotent stem cells. Curr Pharm Des 2009; 15(24): 2791-2806.
82. Nussbaum J, Minami E, Laflamme MA, Virag JA, Ware CB, Masino A, et al. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J 2007; 21(7): 1345-1357.
83. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011; 474(7350): 212-215.
84. English K, Wood KJ. Immunogenicity of embryonic stem cellderived progenitors after transplantation. Curr Opin Organ Transplant 2010; 11 (9).
85. Karabekian Z, Posnack NG, Sarvazyan N. Immunological barriers to stem-cell based cardiac repair. Stem Cell Rev 2011; 7(2): 315-325.
86. Zimmermann WH, Melnychenko I, Eschenhagen T. Engineered heart tissue for regeneration of diseased hearts. Biomaterials 2004; 25(9): 1639-1647.
87. Brooks, M.N., Watson J.P. Tissue engineering in vivo with vascularized scaffolds. US7846728 (2010).
88. Hollister, S.J., G.T.M. Chu, and J.M. Taboas, Design methodology for tissue engineering scaffolds and biomaterial implants. US7174282 (2007).
89. Dennis, R.G., Birla, R.K., Boluyl, M.O., Arruda, E.M., Baar, K.R., Borschel, G.H., System and method for forming a cardiac muscle construct. US7338798 (2008).